Title: Updated Health Opportunity Cost Estimates for 92 Low- and Middle-Income Countries: Implications for Global Health Financing and Donor Allocation

Authors and Affiliations

Jessica Ochalek MPH, MSc, PhD[1]

[1]Centre for Health Economics, University of York, United Kingdom

Corresponding author – Jessica Ochalek, Centre for Health Economics, University of York, Heslington, York, YO10 5DD, jessica.ochalek@york.ac.uk, Tel: +44 1904 321442

Funding statement

This study was supported by the Center for Global Development, through the Foreign Commonwealth and Development Office, project code: 301528-401, and Coefficient Giving.

Author confirmation

This work was carried out as private consultancy by the author. Although the author is otherwise employed by a university, the work and recommendations produced in this paper do not imply an endorsement or commitment from that university. (Identifying information redacted for anonymity.)

Ethical statement
Ethical approval was not required for this study.

Competing interest statement
None to declare.

Abstract

Estimates of the marginal cost per disability-adjusted life year (DALY) averted from government health expenditure (GHE) provide an empirical basis for allocating scarce health resources to maximise population health. Existing cross-country estimates have informed priority setting in several countries and international policy discussions but are based on data that are now more than a decade old. Since then, patterns of health expenditure, disease burden, and global health financing have changed substantially.

This paper provides updated estimates of the marginal cost per DALY averted for 92 low- and middle-income countries (LMIC) by applying previously estimated elasticities of the effect of GHE on health outcomes from Ochalek et al. (2018) to recent data on mortality, morbidity, population structure, and GHE. Two policy options for improving health in LMIC are assessed: (1) the implications of countries allocating 15% of general government expenditure to health consistent with the Abuja Declaration; and (2) reallocating development assistance for health (DAH) to maximise health across countries. Scenario analyses use the estimated elasticities to reflect diminishing marginal returns to health expenditure when calculating the health gains associated with additional resources.

Updated estimates of the marginal costs per DALY averted range from approximately $78 to $15,789 across countries. In most countries (72%), estimates are higher than in the previous analysis, largely reflecting increases in GHE. Increasing domestic expenditure to achieve the Abuja Declaration objective would avert 234 million DALYs but require $563 billion across countries. Reallocating $39.1 billion in existing DAH could avert 133.6 million DALYs.

Updated estimates provide an empirical basis for informing both domestic priority setting and the allocation of international health financing. Aligning donor funding with country-specific opportunity costs could substantially increase the global health gains achieved with limited resources.

Introduction

All health systems face resource constraints and difficult trade-offs about what healthcare to provide with pooled government funds. Every additional government dollar spent on health carries an opportunity cost: financing one intervention inevitably displaces another which would also have generated health. These constraints are typically more binding, and the trade-offs more consequential, in low- and middle-income countries (LMIC), where fiscal space is limited, disease burdens are higher, and many highly cost-effective essential services remain underfunded. The situation has become more acute amid tightening fiscal conditions and declining external support. External aid for health fell 21% between 2024 and 2025 to $39.1 billion and is projected to continue to decline to $36.2 billion by 2030 (Apeagyei et al., 2025; Institute for Health Metrics and Evaluation (IHME), 2025). 1.38 billion people around the world are living in LMIC which are both highly exposed to US global health aid cuts and highly fiscally constrained (Baker et al., 2025).

Country-specific estimates of the marginal cost per DALY averted from government health expenditure (GHE) are critical for informing priority setting within health systems. These estimates reflect the health that a marginal increase in expenditure would generate (or equivalently, the health that would be forgone from a marginal reduction in expenditure). These estimates can be used to provide a benchmark (e.g., a cost-effectiveness threshold) for assessing whether new interventions or programmes are likely to increase or reduce population health (Chi et al., 2020). They can also be used to quantify the extent to which interventions or programmes will increase or reduce population health (i.e., net health effect) (Claxton et al., 2016; Paulden, 2020). This type of analysis has been used to inform health benefits package design in Malawi and Uganda (Mohan et al., 2023; Ochalek, Revill, et al., 2018) and decisions around the expansion or contraction of bundles of services in Ghana (Vellekoop et al., 2022).

It can also be used to inform the health consequences of broader changes in GHE (Lomas et al., 2025). One potential response to cuts in donor funding would be for countries to increase domestic funding for healthcare. Such increases were already a policy objective for countries under the Abuja Declaration in 2001, where they pledged to allocate at least 15% of their annual budget to GHE (World Health Organization, 2010). As of writing, however, well over half of LMIC have yet to meet this target. Estimates of the marginal cost per DALY averted can inform the health effects of expanding GHE.

Such estimates are also important for informing donor resource allocation decisions around what programmes to invest in and in which healthcare systems. Amid the backdrop of cuts to health aid, there is renewed urgency for methods that can guide more effective donor engagement and align external financing with national priorities. One prominent reform proposal is the “New Compact” for global health financing, which seeks to rebalance responsibilities between governments and donors. The New Compact is based on three pillars that reflect a shared responsibility between a country and its donors: (1) evidence-informed, locally led prioritization; (2) domestic-first resource allocation, with donor support for interventions that are only marginally cost-effective at the country level; and (3) consolidated supplementary aid (Drake et al., 2025b; Morton et al., 2018, 2024). By shifting donors away from earmarked disease-specific funding toward supporting marginal expansions of nationally determined service packages, the New Compact implies a need to

consider opportunity costs and the marginal productivity of health expenditure when making financing decisions. Operationalising such an approach requires estimates of the marginal productivity of health expenditure across countries reflecting health opportunity costs in each country. Without this empirical foundation, calls for domestic-first financing and consolidated supplementary aid remain conceptually appealing but difficult to implement in practice.

The opportunity cost of expenditure on a given intervention for a specific disease or population falls across the population that benefits from healthcare expenditure. Therefore, consideration of opportunity cost requires a common measure of health that enables comparison across the range of services and interventions that may be provided by the healthcare system. The disability-adjusted life year (DALY) provides such a measure by capturing both premature mortality and time lived with disability. Expressed as DALYs averted, health gains from interventions that extend life, improve quality of life, or both can be compared on a common scale, enabling prioritisation across the full range of health services within a national package. Another measure that has been used is quality-adjusted life years (QALYs), which capture changes in both survival and health-related quality of life and are widely used in health technology assessment in high-income countries. Estimating QALYs requires preference-based health state value sets (e.g., EQ-5D tariffs), which have historically been unavailable in many LMIC (Sultana et al., 2026). Estimates of the marginal cost per DALY averted or QALY gained from GHE are currently available for only a small number of countries (13 at the time of writing) (Murphy, Griffin, Walker, Vallejo-Torres, Espinosa, Gloria, et al., 2026). Estimation is data intensive and can take years (Edney et al., 2022). A 2018 study by Ochalek et al. provided cross-country estimates of the marginal productivity of health expenditure and corresponding estimates of the marginal cost per DALY averted (Ochalek, Lomas, et al., 2018). However, the global health financing landscape has changed over the last decade. Patterns of health expenditure have shifted, disease burdens have evolved, demographic structures have aged in many settings, and donor funding levels have become more volatile. Up to date estimates are required to better inform domestic and international decision-making around allocating funding for healthcare.

This paper provides updated estimates of the marginal cost per DALY averted and uses these to model the potential responses to changes in the donor funding landscape. We first examine the implications for cost per DALY averted estimates of governments allocating 15% of national budgets to health, as per the Abuja Declaration, and then assess the health effects of allocating DAH according to New Compact principles.

Methods

We update country-specific estimates of the marginal cost per DALY averted using the health opportunity cost framework developed by Ochalek et al. (2018). Rather than re-estimating the elasticity of health outcomes with respect to GHE, we retain the previously estimated central elasticity parameter and update the underlying country-level inputs. This approach assumes that the proportional responsiveness of health outcomes to expenditure remains stable over time, while allowing baseline levels of expenditure, disease burden, and population to evolve.

Following Ochalek et al. (2018), we construct four alternative DALY-based measures (DALYs 1–4) to ensure consistency with the underlying elasticity estimates. The first

measure is grounded in mortality data and uses the estimated elasticity of mortality with respect to expenditure to calculate DALYs averted. The second measure relies on the elasticity of survival (years of life lost, YLLs) with respect to expenditure. The third measure combines the elasticities of survival and morbidity (years lived with disability, YLDs), applying each to the corresponding burden component. The fourth measure applies the elasticity estimated directly for DALYs. See Appendix A for details. For each measure, the relevant elasticity is applied to the updated country-level outcome data to estimate DALYs averted. This results in four estimates of DALYs averted and we also calculate the average DALYs averted across the four estimates for presentational purposes.

Cost per DALY averted is calculated from a 1% proportional increase in GHE. GHE is defined as spending through government schemes, including tax-based financing, compulsory contributory health insurance schemes and on budget donor support. For each country, the estimated percentage change in the relevant health outcome associated with a 1% expenditure increase is converted into absolute DALYs averted using updated healthcare expenditure, demographic, mortality and morbidity data, and the marginal cost per DALY averted is calculated.

We present results for each country both as an absolute cost per DALY averted and as a proportion of 1x and 0.5x GDP per capita. Expressing estimates relative to GDP per capita facilitates comparison with historically used cost-effectiveness benchmarks, which, despite well-documented limitations, remain influential in policy discussions and global health decision-making (e.g., influencing cost-effectiveness analysis in Disease Control Priorities, Third Edition) (Bertram et al., 2016; Chi et al., 2020; Horton, 2017; Murphy, Griffin, Walker, Vallejo-Torres, Espinosa, Ardy, et al., 2026).

Such estimates are appropriate for calculating health effects of marginal changes in expenditure, but they do not reveal the relationship between health and expenditure for more substantial quantities. Consistent with the underlying econometrics, which estimates the effect as an elasticity, there are likely diminishing marginal returns in this relationship. This means that the absolute cost per DALY at the margin is increasing with expenditure (Lomas et al., 2025).

We adopt the approach outlined in Appendix C of Lomas et al. (2025) (Lomas et al., 2025), which enables us to evaluate different scenarios for how resources (whether domestic or donor) could be allocated (domestically if the former and internationally if the latter) to improve global health. For ease of exposition, we base our analysis on DALY 4 since this is based on one estimated elasticity. Since DALY 4 is neither the upper nor lower end of the range of estimates DALYs 1-4 for any country, results based on this should be regarded as broadly representative of our results more generally.

To examine the implications of governments allocating 15% of national budgets to health, as per the Abuja Declaration (*Public Finances in Modern History - Government Expenditure, Percent of GDP*, n.d.), we calculated the additional GHE required in countries where current domestic general GHE accounts for less than 15% of general government expenditure.

Domestic general government expenditure per capita (current US$) was calculated using data on domestic general GHE per capita and domestic general GHE as a percentage of

general government expenditure. The latter was converted to a proportion prior to calculation (see Methods). For each country, the target level of health expenditure per capita consistent with a 15% budget allocation was calculated as:

$$(1)\ GHE_{pc}^{target} = 0.15 \times GGE_{pc}$$

where GGE_{pc} denotes domestic general government expenditure per capita.

The additional expenditure required per capita was calculated as:

$$(2)\ \Delta GHE_{pc} = \max\left(0,\ GHE_{pc}^{target} - GHE_{pc}\right)$$

where GHE_{pc} denotes observed domestic general GHE per capita. Countries already allocating at least 15% of general government expenditure to health were assigned a value of zero additional requirement. Total additional expenditure requirements were calculated by multiplying ΔGHE_{pc} by country population in 2023 corresponding to the year for which the most recent GHE and GGE data are available.

The number of DALYs per capita for a country can be expressed as a power function:

$$(3)\ DALY_{pc} = \alpha \times GHE_{pc}{}^{-\beta}$$

where β denotes the magnitude of the estimated elasticity on DALYs, $DALY_{pc}$ represents the DALYs per capita and GHE_{pc} is the GHE per capita. α is unknown but is solved for each country given the observed and estimated values for other parameters. We calculate the health gains of all countries achieving the objective of spending 15% of GGE on GHE as the difference in health gains between the original expenditure level and 15% for countries that were spending less than that as a percent of GGE:

$$(4)\ \sum_{n=1}^{i} DALYs^{target\ expenditure} - DALYs^{original}$$

To evaluate the health impact of the second potential policy response, we consider an optimal allocation of all donor resources across countries Ω (inclusive of both on- and off-budget support) to achieve the greatest reduction in DALYs globally. We begin by removing the on-budget support component (using the estimate from the World Bank for each country) from GHE, re-calculating the DALYs using Equation 3. From this baseline we consider an optimal allocation of all DAH across countries Ω.

$$(5)\ Min \sum DALY\ \ subject\ to \sum DAH \leq \Omega$$

Total DAH (the sum of on- and off-budget support) measured by the World Bank is lower than that measured by IHME. On-budget support makes nearly half of donor funding for countries in our sample using World Bank data. This likely reflects that by focusing on funding captured in national accounts World Bank estimates may under capture NGO-delivered programmes and vertical programmes run outside government systems. As such, we apply the more realistic estimate of $39.1 billion for 2025 from the Institute for Health

Metrics for all DAH across countries.[1] Obtaining the allocation of DAH that maximises health globally is achieved by iteratively re-allocating each additional dollar to the country with the lowest cost per DALY averted given the new global allocation.

Public and patient involvement

Patients and the public were not involved in this study. The analysis is based on secondary, aggregated data from publicly available sources and does not involve individual-level patient data. The study addresses system-level resource allocation and priority-setting questions, which are intended to inform policy decisions affecting population health.

Data

Updating the estimated marginal cost per DALY averted requires country-level data on mortality and life expectancy (conditional on age at death), disaggregated by age and sex, as well as years lived with disability (YLDs). These are obtained from the most recent Global Burden of Disease (GBD) release via the Global Health Data Exchange (GHDx) (Global Burden of Disease Collaborative Network, 2026). Consistent with the methodology described in Ochalek et al. (2018), these inputs are used to construct the four DALY measures described above.

GHE includes spending through government schemes and compulsory contributory health care financing schemes, irrespective of the original revenue source, including external funds channelled through government budgets (OECD/Eurostat/WHO, 2017). Data for this variable are drawn from the World Bank National Health Accounts (The World Bank, 2026).[2] Consistent with previous analysis, our expenditure measure excludes voluntary health care payment schemes and household out-of-pocket payments (OOPs) and off-budget donor funding (i.e., direct foreign transfers). For further discussion of the role of OOPs in health opportunity cost estimation, see Ochalek et al. (forthcoming). The World Bank provide additional information on per capita on- and off-budget support received by countries drawn from national health accounts in the first instance, and where this information is incomplete, surveys and reports from donors, governments, non-profit institutions may also be used (World Health Organization, 2025). The Institute for Health Metrics and Evaluation (IHME) publish data on donor assistance for health (DAH) further disaggregated by source, channel of funding, and health focus and programme areas. It draws on donor project databases, financial statements, annual reports, IRS 990s, and correspondence with agencies (Institute for Health Metrics and Evaluation (IHME), 2024).

GDP per capita data are also obtained from the World Bank (The World Bank, 2026). These are used both to contextualise cost-per-DALY estimates and to express results as a

[1] This includes DAH for countries excluded from our sample.
[2] Health expenditure managed through government schemes and compulsory contributory schemes (HF.1) includes: transfers from government domestic revenue (allocated to health purposes); transfers distributed by government from foreign origin; social insurance contributions; compulsory prepayment (other, and unspecified, than FS.3); and unspecified revenues of health care financing schemes (n.e.c.).

proportion of national income. Countries are classified into income groups according to the World Bank country and lending groups for 2023 (The World Bank, 2026a, 2026b).[3]

Domestic general government expenditure per capita was not directly available for all countries and years. We therefore calculated it using reported domestic general GHE per capita and domestic general GHE as a share of total general government expenditure from the World Bank (The World Bank, 2026c). Since:

$$(6)\ \text{Health Share} = \frac{GHE}{GGE}$$

total domestic general government expenditure per capita was calculated as:

$$(7)\ GGE_{pc} = \frac{GHE_{pc}}{\text{Health Share}}$$

where health share is expressed as a decimal. This approach preserves consistency with national health accounts definitions and avoids mixing expenditure concepts (e.g., government final consumption expenditure).

Results

We estimate marginal cost per DALY averted for 92 LMIC.[4] For most countries in the analysis (72%, 66 of 92) the estimated marginal cost per DALY averted is higher in the current analysis than the previous analysis (Ochalek et al, 2018). Among the 26 countries for which the estimate is lower, this change is closely associated with trends in GHE between 2014 and 2023. In 22 of these 26 countries, GHE declined over this period. By contrast, in 55 of the 66 countries where the estimated marginal cost per DALY averted is higher in the current analysis, GHE increased between 2014 and 2023. Differences in changes in YLLs and total DALYs between the two groups are present but modest compared to changes in GHE.

In addition to changes over time, revisions to the underlying expenditure data also contribute to differences relative to the previous analysis. Comparing the estimate of GHE for 2014 in the updated dataset with the value originally used in the 2018 analysis shows that, among countries where the marginal cost per DALY averted has decreased, the revised 2014 GHE estimate is lower in all but three cases. The exceptions are Brazil (+4%), Colombia (+5%), and Lebanon (no change). For most of the remaining countries, the downward revision is in the range of 10–20%, although there are notable outliers, including The Gambia (–71%) and the Republic of the Congo (–6%). These patterns suggest that both realised expenditure trends and retrospective revisions to expenditure data contribute to the observed changes in estimated marginal productivity.

Figure 1 gives point estimates for the cost per DALY averted from DALY 4, the preferred estimate. The bars show the range of cost per DALY averted estimates across the four

[3] Venezuela was not classified in the most recent World Bank Group income classifications for 2023. We use the most recent classification from 2019,

[4] Five countries that were included in the 2018 analysis are excluded from this analysis as they have moved out of the LMIC category into the high-income country category: Bulgaria, Guyana, Panama, Romania, Russia

methods of calculating DALYs averted from the data. Consistent with 2018 analysis, most (85 out of 91) LMIC for which we are able to estimate the marginal cost per DALY averted have average estimates below 1x GDP per capita.[5]



The estimated marginal cost per DALY averted from DALY 4 ranges from $78-695 (2026 US) in low-income countries, $80-5,004 (2026 US) in lower middle-income countries, and $860-15,789 in upper middle-income countries. Cost per DALY averted for each country from DALY 4 is reported in Table 1. (All estimates are reported in Appendix B.)

Among countries in our analysis GHE as a percent of GGE ranges from 2 to 26%, and 76 countries (84%) spend less than 15% of GGE on health. Reaching 15% would avert 234 million DALYs, but would require an increase in spending across countries of $563 billion (i.e., a 35% increase in GHE across countries). 54% of countries (49 countries) spend less than 10% of GGE on GHE. A much smaller 8% increase in GHE across these countries (totalling $91 billion) would avert nearly half as many (112 million) DALYs.

According to the World Bank, 80 of 91 countries in our analysis are recipients of on-budget support from donor aid for health, totalling $12.3 billion. This aid, as currently allocated averts 45.3 million DALYs.[6] Reallocating this pot of money according to where it would have the greatest health benefit would avert 71.1 million DALYs. Optimally allocating the total $39.1 billion DAH budget envelope for 2025 according to where it can generate the greatest benefit for health would avert 133.6 million DALYs across 38 countries. This involves moving existing on-budget support from all upper-middle income countries and some lower-middle income countries to other low- and lower-middle income countries. Consequentially, the marginal cost per DALY averted in some countries would be lower following reallocation. For

[5] Eritrea is excluded from this calculation and the figure, as there was no data for GDP per capita for any year from 2015 to current.
[6] Recent data on the split between on- and off-budget support is not available for Ukraine.

example, a portion of the DAH that goes to India, a lower-middle income country where the estimated cost per DALY averted is $609, would be diverted to other countries resulting in the cost per DALY averted for India reducing to $601. The reallocation of funding would mean that the lowest cost per DALY averted across all countries is $599.

[INSERT TABLE 1]

Discussion

This paper provides updated marginal cost per DALY averted estimates for 92 LMIC. For most countries, the estimated marginal cost per DALY averted is higher than in the previous analysis of cross-country data from 2018. However, as with the previous analysis, this paper finds that most estimates of cost per DALY averted are below 1x GDP per capita, reinforcing the earlier finding that applying GDP per capita based cost-effectiveness thresholds to funding and prioritisation decisions risks reducing overall population health.

Patterns of health expenditure, disease burden, and demographic structures in countries have changed between the studies. Each of these influences the cost per DALY averted. All else equal, a decrease in mortality would result in a higher cost per DALY averted; because baseline mortality is lower, the same percentage change in mortality for a given percentage change in expenditure is lower. However, these factors interact, and the implied cost per DALY averted ultimately reflects the opportunity cost of expenditure within the mix of funded services (Paulden et al., 2017).

The increase in cost per DALY averted in this analysis across most countries is largely driven by increases in GHE over time, reflecting movement along a concave health production function in which, all else equal, marginal returns diminish as spending increases (Bokhari et al., 2007; Lomas et al., 2025). In a minority of countries, declines in GHE between the periods of analysis or revisions to historical expenditure data contributed to lower estimated costs per DALY averted. Where this follows revisions to historical expenditure data, this suggests that GHE is in fact more productive than previously estimated.

These updated estimates provide a basis for countries to assess not only whether new interventions generate more health than they displace, but the magnitude of the gains or losses (Claxton et al., 2016; Paulden, 2020). In doing so, they strengthen locally led, evidence-informed priority-setting processes. Beyond informing domestic priority setting, these estimates have direct implications for how scarce donor resources should be allocated across countries.

If the objective of donors is to maximise global health gains, then resources should be directed to settings where the marginal productivity of health expenditure is highest, that is, where the cost per DALY averted is lowest. The current best estimate of on-budget support as currently allocated averts 45.3 million DALYs, while allocating it in line with country-specific opportunity costs would avert approximately 71.1 million DALYs by moving some of this funding from countries where it generates less health benefit to countries where it generates more health benefit. This reflects that the health returns to spending vary substantially across countries. Ignoring this variation leads to large losses in potential health

gains. A donor strategy that explicitly accounts for these differences by allocating funds at the margin where they generate the greatest health can therefore achieve markedly greater impact without increasing total spending. Allocating the total pot of on- and off-budget DAH, estimated to be $39.1 billion, in line with country-specific opportunity costs could avert approximately 133.6 million DALYs.

Raising domestic spending to 15%, or even 10%, of general government expenditure would require significant increases in domestic spending on health. The spend required to reach this target far outstrips current DAH underscores the challenge of doing so. In the context of constrained and declining donor funding (University of Washington, 2026), it is increasingly important for countries to strengthen domestic resource mobilisation for health, while ensuring that both domestic and external funds are allocated where they generate the greatest health gains.

In the scenario analyses additional financing, whether financed domestically or through donors, is treated as augmenting domestic health spending without altering the underlying health production function. This implies that domestic and donor-financed expenditure are considered interchangeable with GHE with respect to their productivity at the margin. In practice, donor funding may interact with domestic spending through mechanisms including crowd-out, co-financing requirements, or institutional strengthening that affects the productivity of health systems. The estimates presented here should therefore be interpreted as approximating the health gains from additional resources entering the health system under the assumption that the productivity of expenditure is invariant to its financing source. Other papers have assessed different types of investments in healthcare and further research in this area would be valuable (Hallett et al., 2025).

Recent analysis has argued that achieving value for money in global development requires moving beyond short-term project metrics toward strengthening national priority-setting systems, supporting domestic co-financing, consolidating fragmented funding streams, and aligning donor investments with recipient government priorities (Drake & Baker, 2025). A central recommendation is that aid should increasingly focus on helping countries use their own resources more effectively, thereby generating durable improvements in health system performance that outlast direct donor involvement. Under a New Compact model of global health financing, where countries assume greater responsibility for financing core services and donors provide coordinated support at the margin, credible opportunity cost estimates become a foundational input (Drake et al., 2025a). Investments in common goods that strengthen health systems may yield significant health gains, and quantifying their potential net health effects across countries requires estimates of the costs, expected benefits and the opportunity cost of such investments in each country (Ochalek, Revill, et al., 2018).

Such an approach has been proposed in the UK where recent reductions in bilateral aid budgets, including those of the UK Foreign, Commonwealth & Development Office (FCDO), have intensified scrutiny of how limited development resources are allocated (Drake & Baker, 2025; UK Parliament, 2026a). UK parliamentary and policy discussions on value for money have emphasised that, in a constrained fiscal environment, aid must demonstrably maximise impact while supporting long-term sustainability (UK Parliament, 2026b). In this context, calls for a renewed focus on efficiency, domestic resource mobilisation, and institutional strengthening are particularly salient.

In addition to informing allocation across countries, country-specific estimates of the marginal cost per DALY averted can inform value-based pricing within pooled procurement arrangements. Under pooled mechanisms, for example for vaccines, antiretrovirals, or other high-impact interventions, suppliers negotiate prices across multiple participating countries (UK FCDO, 2026). Aligning such negotiations with country-specific opportunity cost estimates enables pooled procurement bodies to define price ceilings consistent with the health that would otherwise be displaced within each health system (Ochalek et al., 2020). In this way, pooled procurement can move beyond securing lower prices in absolute terms toward ensuring that negotiated prices are consistent with net health gains across countries.

By providing updated, country-specific estimates of the marginal productivity of health expenditure, this study equips both donors and governments with empirical evidence to inform assessments of the health value of additional spending, whether domestic or external. In a context of shrinking aid envelopes, such estimates become even more important as they help to ensure that scarce donor resources are directed to settings where marginal health gains are greatest, while also strengthening domestic priority-setting institutions to improve the efficiency of nationally financed spending.

Several limitations warrant consideration. First, we retain previously estimated elasticity parameters and update the underlying country-level inputs. If the relationship between expenditure and health outcomes has structurally changed over time, our estimates may not fully capture this. This should be a priority for future research. Second, scenario modelling is based on one of the four DALY measures for tractability, though results are broadly representative across specifications. Third, the analysis excludes out-of-pocket expenditure and focuses on government and compulsory contributory schemes, consistent with the underlying framework. The relationship between GHE and out-of-pocket expenditure is discussed elsewhere (forthcoming). Fourth, estimates are derived at the national level and do not capture within-country heterogeneity or political feasibility constraints.

These limitations, however, do not alter the central implication: opportunity costs differ substantially across countries and evolve over time, with important consequences for both domestic and donor allocation decisions. Regularly updating opportunity cost estimates is essential, particularly so in a context where both domestic budgets and donor financing are volatile. Static thresholds based on historical data risk misrepresenting current trade-offs and undermining efficient priority setting. While the results shows that a reallocation of donor funding could achieve a minimum cost per DALY averted across all countries, the contribution of this study is not to propose a single universal threshold but instead to provide updated empirical estimates of country-specific opportunity costs that can inform both domestic and donor decision rules.

Conclusion

In a context of tightening fiscal space and declining external assistance, the opportunity cost of misallocation of resources for healthcare is more relevant than ever. Updated estimates of the marginal cost per DALY averted across countries can inform decisions around how to allocate government resources for health, as well as informing domestic-first financing and

consolidated supplementary aid under a New Compact for global health financing. Aligning donor support with country-specific opportunity costs can maximise health gains.

References

Apeagyei, A. E., Bisignano, C., Elliott, H., Hay, S. I., Lidral-Porter, B., Nam, S., Shyong, C., Tsakalos, G., Zlavog, B. S., Barış, E., Murray, C. J. L., & Dieleman, J. L. (2025). Tracking development assistance for health, 1990–2030: historical trends, recent cuts, and outlook. *The Lancet*, *406*(10501), 337–348. https://doi.org/10.1016/S0140-6736(25)01240-1

Baker, P., Klemperer, K., Hughes, S., Madan Keller, J., & Guzman, J. (2025). *26 Countries Are Most Vulnerable to US Global Health Aid Cuts. Can Other Funders Bridge the Gap?* https://www.cgdev.org/blog/26-countries-are-most-vulnerable-us-global-health-aid-cuts-can-other-funders-bridge-gap

Bertram, M. Y., Lauer, J. A., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. R. (2016). Cost-effectiveness thresholds: pros and cons. *Bulletin of the World Health Organization*, *94*(12), 925–930. https://doi.org/10.2471/BLT.15.164418

Bokhari, F. A. S., Gai, Y., & Gottret, P. (2007). Government health expenditures and health outcomes. *Health Economics*, *16*(3), 257–273. https://doi.org/10.1002/hec.1157

Chi, Y.-L., Blecher, M., Chalkidou, K., Culyer, A., Claxton, K., Edoka, I., Glassman, A., Kreif, N., Jones, I., Mirelman, A., Nadjib, M., Morton, A., Norheim, O. F., Ochalek, J., Prinja, S., Ruiz, F., Teerawattananon, Y., Vassall, A., & Winch, A. (2020). What next after GDP-based cost-effectiveness thresholds? *Gates Open Research*, *4*, 176. https://doi.org/10.12688/gatesopenres.13201.1

Claxton, K., Ochalek, J., Revill, P., Rollinger, A., & Walker, D. (2016). *Informing Decisions in Global Health: Cost Per DALY Thresholds and Health Opportunity Costs* (Policy and Research Briefing). https://www.york.ac.uk/media/che/documents/policybriefing/Cost%20per%20DALY%20thresholds.pdf

Drake, T., & Baker, P. (2025, February 19). *Achieving Value for Money in Global Development: Six Recommendations for the FCDO | Center For Global Development*. https://www.cgdev.org/blog/achieving-value-money-global-development-six-recommendations-uk-fcdo

Drake, T., Ochalek, J., Więcek, W., Yakhelef, N., & Bonnifield, R. (2025a). *A New Compact for Health Financing: Donor Priority Setting* (386; CGD Note).

Drake, T., Ochalek, J., Więcek, W., Yakhelef, N., & Bonnifield, R. (2025b, June 30). *A New Compact for Health Financing: Donor Priority Setting*. CGD Note.

Edney, L. C., Lomas, J., Karnon, J., Vallejo-Torres, L., Stadhouders, N., Siverskog, J., Paulden, M., Edoka, I. P., & Ochalek, J. (2022). Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. *PharmacoEconomics*, *40*(1), 31–43. https://doi.org/10.1007/S40273-021-01087-6/FIGURES/1

Global Burden of Disease Collaborative Network. (2026). *Global Burden of Disease Study 2023 (GBD 2023) Results*. Institute for Health Metrics and Evaluation (IHME).

Hallett, T. B., Mangal, T. D., Tamuri, A. U., Arinaminpathy, N., Cambiano, V., Chalkley, M., Collins, J. H., Cooper, J., Gillman, M. S., Giordano, M., Graham, M. M., Graham, W., Hawryluk, I., Janoušková, E., Jewell, B. L., Lin, I. L., Manning Smith, R., Manthalu, G.,

Mnjowe, E., … Phillips, A. N. (2025). Estimates of resource use in the public-sector health-care system and the effect of strengthening health-care services in Malawi during 2015–19: a modelling study (Thanzi La Onse). *The Lancet Global Health*, *13*(1), e28–e37. https://doi.org/10.1016/S2214-109X(24)00413-3

Horton, S. (2017). Cost-Effectiveness Analysis in Disease Control Priorities, Third Edition. In D. T. Jamison, H. Gelband, S. Horton, P. Jha, R. Laxminarayan, C. N. Mock, & R. Nugent (Eds.), *Disease Control Priorities in Developing Countries* (3rd Editio, Chapter 7). The World Bank.

Institute for Health Metrics and Evaluation (IHME). (2024). *Development Assistance for Health Database 1990-2023*.

Institute for Health Metrics and Evaluation (IHME). (2025). *Financing Global Health 2025: Cuts in Aid and Future Outlook*.

Lomas, J., Longo, F., Salas-Ortiz, A., & Claxton, K. (2025). *Estimating the health benefits of increasing and reallocating expenditure on the National Health Service in England (with appendices)*. https://doi.org/10.15131/SHEF.DATA.30719684.V2

Mohan, S., Walker, S., Sengooba, F., Kiracho, E. E., Mayora, C., Ssennyonjo, A., Aliti, C. T., & Revill, P. (2023). Supporting the revision of the health benefits package in Uganda: A constrained optimisation approach. *Health Economics (United Kingdom)*, *32*(6), 1244–1255. https://doi.org/10.1002/hec.4664

Morton, A., Arulselvan, A., & Thomas, R. (2018). Allocation rules for global donors. *Journal of Health Economics*, *58*, 67–75. https://doi.org/10.1016/j.jhealeco.2018.02.003

Morton, A., Briones, J., Demeshko, A., Baker, P., & Drake, T. (2024). *A New Compact for Financing Health Services: Opportunities for Gavi and Partner Countries* (338; Policy Paper). www.cgdev.org

Murphy, P., Griffin, S., Walker, S., Vallejo-Torres, L., Espinosa, O., Ardy, M., Gloria, J., & Ochalek, J. (2026). Cost-effectiveness thresholds in policy and practice: do HTA guidelines align with estimates of health opportunity cost? *Health Economics, Policy and Law*, 1–29. https://doi.org/10.1017/S1744133126100395

Murphy, P., Griffin, S., Walker, S., Vallejo-Torres, L., Espinosa, O., Gloria, M. A. J., & Ochalek, J. (2026). Cost-Effectiveness Thresholds in Policy and Practice: Do HTA Guidelines Align with Estimates of Health Opportunity Cost? *Health Economics, Policy and Law*.

Ochalek, J., Abbas, K., Claxton, K., Jit, M., & Lomas, J. (2020). Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. *BMJ Global Health*, *5*(10), e003006. https://doi.org/10.1136/bmjgh-2020-003006

Ochalek, J., Lomas, J., & Claxton, K. (2018). Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. *BMJ Global Health*, *3*(6), e000964. https://doi.org/10.1136/bmjgh-2018-000964

Ochalek, J., Revill, P., Manthalu, G., McGuire, F., Nkhoma, D., Rollinger, A., Sculpher, M., & Claxton, K. (2018). Supporting the development of a health benefits package in Malawi. *BMJ Global Health*, *3*(2), e000607. https://doi.org/10.1136/bmjgh-2017-000607

OECD/Eurostat/WHO. (2017). *A System of Health Accounts 2011: Revised edition*. https://www.oecd.org/en/publications/a-system-of-health-accounts-2011_9789264270985-en.html

Paulden, M. (2020). Calculating and Interpreting ICERs and Net Benefit. *PharmacoEconomics*, *38*(8), 785–807. https://doi.org/10.1007/S40273-020-00914-6/TABLES/18

Paulden, M., O'Mahony, J., & McCabe, C. (2017). Determinants of Change in the Cost-effectiveness Threshold. *Medical Decision Making*, *37*(2), 264–276. https://doi.org/10.1177/0272989X16662242

Public Finances in Modern History - Government expenditure, percent of GDP. (n.d.). Retrieved February 19, 2026, from https://www.imf.org/external/datamapper/exp@FPP/USA/FRA/JPN/GBR/SWE/ESP/ITA/ZAF/IND

Sultana, M., Chiu, T., Kamal, M., Kabir, M. A., Ahmed, S., Huque, R., & Khan, J. (2026). Valuation of EQ-5D Health States for Adults in Low-, Lower-Middle, and Upper-Middle-Income Countries: A Systematic Review. *Value in Health Regional Issues*, *51*, 101505. https://doi.org/10.1016/j.vhri.2025.101505

The World Bank. (2026a). *World Bank Country and Lending Groups – World Bank Data Help Desk*. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups

The World Bank. (2026b). *World Bank country classifications by income level for 2024-2025*. https://blogs.worldbank.org/en/opendata/world-bank-country-classifications-by-income-level-for-2024-2025

The World Bank. (2026c). *World Development Indicators | DataBank*. https://databank.worldbank.org/reports.aspx?source=2&series=NE.CON.GOVT.CD&country=#

UK FCDO. (2026). *Gavi Submission to the UK International Development Committee's Inquiry into FCDO's Approach to Value for Money*.

UK Parliament. (2026a). *The FCDO's approach to value for money*. https://committees.parliament.uk/work/8624/the-fcdos-approach-to-value-for-money/publications/

UK Parliament. (2026b). *The FCDO's approach to value for money - Written evidence*. https://committees.parliament.uk/work/8624/the-fcdos-approach-to-value-for-money/publications/written-evidence/?page=2

University of Washington. (2026). *Health financing*. https://www.healthdata.org/research-analysis/health-financing

Vellekoop, H., Odame, E., & Ochalek, J. (2022). Supporting a review of the benefits package of the National Health Insurance Scheme in Ghana. *Cost Effectiveness and Resource Allocation 2022 20:1*, *20*(1), 1–14. https://doi.org/10.1186/S12962-022-00365-0

World Health Organization. (2010). *The Abuja Declaration: Ten Years On 2001 Promises of commitment and solidarity*. https://iris.who.int/server/api/core/bitstreams/b52f7a63-fe72-4dbb-ae0e-0b09651c32e1/content

World Health Organization. (2025). *Methodology for the update of the Global Health Expenditure Database*. https://iris.who.int/.